Page 306 - Read Online

Hu et al. Hepatoma Res 2019;5:29 I http://dx.doi.org/10.20517/2394-5079.2019.23 Page 5 of 6

Secondary prevention of HBV-associated HCC plays a key role in reducing the incidence of HCC, finding
the occurrence of small HCC, carrying out early surgical treatments, and prolonging the survival cycle of
patients, which deserved to be widely popularized.

DECLARATIONS
Authors’ contributions
Collected the data and drew figures: Hu BB
Drafted the manuscript: Wang RM
Obtained the funding and revised the paper: Jiang JN

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by grants from Natural Science Foundation of Guangxi Key Laboratory for the
Prevention and Control of Viral Hepatitis (GXCDCKL201802) and was funded by Key laboratory of High-
Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education (GKE2018-05),
and National Science and Technology Major Project of China (2017ZX10202201).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Hou JL, Lai W; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical
Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi
2015;23:888-905. (in Chinese)
2. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24.
3. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV
infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.
4. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, et al. Comprehensive analyses of mutations and hepatitis B virus
integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol 2016;51:473-86.
5. Lau CC, Sun T, Ching AK, He M, Li JW, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and
progression. Cancer Cell 2014;25:335-49.
6. Liang HW, Wang N, Wang Y, Wang F, Fu Z, et al. Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via
sequestering cellular microRNA-122. J Hepatol 2016;64:278-91.
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol
2018;69:182-236.
8. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular
carcinoma. Aliment Pharmacol Ther 2008;28:1067-77.
9. Papatheodoridis G V, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, et al. Virological suppression does not prevent
the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)
starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-16.
10. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013;57:399-408.
11. Yang F, Liu WB, Chen L, Tan XJ, Cao GW, et al. Anti-HBV treatment delays development and evolution of HCC. Academic Journal of